1 Global Purified Membrane Protein Market Insight Analysis
The global purified membrane protein market size was valued at USD 465.64 million in 2024, with a CAGR of 14.5% from 2024 to 2033.
A membrane protein is a protein molecule that is attached to, or associated with, the membrane of a cell or an organelle. Protein purification is the processes of isolating a protein of interest from its environment. Purified Membrane Protein is a membrane protein that has undergone a purification step. Purified Membrane Protein is widely used in pharmaceutical companies, biotechnology companies, academic research institutions or teams, etc.
Figure Global Purified Membrane Protein Market Size (M USD) and CAGR (2024-2033)
2 Purified Membrane Protein Market Growth Drivers and Restraints
Driven by the increase in drug varieties: Many patients with life-threatening and debilitating diseases have an urgent need for new drugs, which has prompted pharmaceutical research companies to actively develop new drugs. From 2011 to 2019, the Center for Drug Evaluation and Research (CDER) under the U.S. Food and Drug Administration (FDA) approved an average of about 40 new drugs per year, and 53 new drugs were approved in 2020.
The continuous emergence of new drugs has greatly promoted the development of the downstream market of the purified membrane protein industry. Because in the process of drug development, purified membrane proteins, as key research objects, play an irreplaceable role in drug mechanism research, target screening, etc., providing a strong driving force for the development of the purified membrane protein industry.
Play a key role in downstream applications: membrane proteins account for 20-30% of all human proteins, covering more than 70% of therapeutic targets, and are widely involved in a variety of important biological processes such as cell adhesion, intercellular communication, signal transduction and material transport. In the field of downstream applications, purified membrane proteins have an irreplaceable position.
For example, purified membrane proteins are important basic materials in antibody research and development, small molecule screening, drug discovery, antibody discovery, and clinical drug validation. Its unique structure and functional characteristics make it an indispensable part of these applications, thus driving the growth of market demand for purified membrane proteins.
Driven by the growth of the pharmaceutical market: With the development of the global economy, the growth of the total population, the intensification of an aging society, and the continuous improvement of people’s health awareness, the global pharmaceutical market is showing a trend of rapid expansion. According to Statista data, the total global pharmaceutical market is estimated to reach US$1.48 trillion in 2022.
The growth of the pharmaceutical market has created a broader downstream market space for the purified membrane protein industry. Because in the entire pharmaceutical industry chain, purified membrane proteins are important upstream products, and their market demand is closely related to the development of the pharmaceutical market. The prosperity of the pharmaceutical market means that the demand for purified membrane proteins will also increase accordingly, which in turn promotes the development of the purified membrane protein industry.
Pressure from rising labor costs: Taking the United States as an example, labor costs continue to rise, which poses severe challenges to the production and cost management of purified membrane proteins. In the production process of purified membrane proteins, a large number of highly qualified R&D and production personnel are required, and labor costs account for a high proportion of the total cost. The increase in labor costs has led to an increase in production costs for companies, squeezing their profit margins. This requires companies to more strictly control costs, optimize production processes, and improve production efficiency during the production process, otherwise they will face greater operating pressure.
Strict product requirements and difficult production conversion: Downstream companies have extremely high requirements for the type, quality, and delivery cycle of purified membrane proteins. Due to its diverse and complex application scenarios, products with higher purity, better biological functions, and strong supply capabilities are required. From laboratory research and development to large-scale production, ensuring stable product quality is an important obstacle faced by the purified membrane protein industry.
During the production process, companies need to carefully select process steps and equipment suitable for large-scale production, and strictly control process parameters to ensure that the product remains stable under a wide range of process conditions. However, this process is technically difficult and costly, which is a huge challenge for many companies and limits the development speed of the industry.
3 Technological Innovations in the Purified Membrane Protein Market
Breakthroughs in expression and purification technologies: Various companies have invested in R&D resources to solve the problem of membrane protein purification and characterization. For example, the FoldEZ™ platform developed by Creative BioMart uses an E. coli expression system to guide recombinant proteins to cytoplasmic aggregates (i.e., inclusion bodies), which increases the yield by 10,000 times compared to traditional recombinant membrane protein expression technology, and the yield can usually reach 5-50 mg per liter of cell culture medium.
Subsequently, a series of proprietary purification and refolding steps are performed to obtain functional natural proteins. This technological innovation not only improves production efficiency, but also reduces production costs, making it possible to produce purified membrane proteins on a large scale, helping to meet the growing market demand.
Advances in detection and analysis technologies: CALIXAR introduced Nanotemper’s Monolith X device for membrane protein characterization. The device uses microscale thermophoresis (MST) technology combined with isothermal spectral shift detection, which can accurately detect the interaction between membrane proteins and unlabeled ligands in solution, provide scientists and researchers with accurate ligand binding parameters, and compare the binding characteristics of multiple ligands. This technological advancement helps to conduct in-depth research on the functions and mechanisms of membrane proteins, provides more accurate data support for drug development, and promotes the application and development of purified membrane proteins in drug discovery and other fields.
Integrate resources and expand business: Sygnature Discovery acquires Peak Proteins Ltd. This acquisition enables Sygnature to seamlessly integrate protein production and related structural determination projects, optimize resource allocation and expand business. As a contract research organization, Peak Proteins has rich experience in providing customized soluble and membrane protein reagents and protein structure analysis. Through the acquisition, Sygnature has enhanced its comprehensive strength in drug discovery and research and further consolidated its market position.
Strengthening technological advantages and market competitiveness: Eurofins Discovery acquires CALIXAR, which is a leader in providing high-quality membrane proteins. This acquisition brings Eurofins Discovery key technical capabilities in membrane protein production, especially in the production of membrane proteins for druggable targets. This further consolidates Eurofins Discovery’s scientific leadership in the field of G protein-coupled receptors (GPCRs) and ion channels, enhances its comprehensive technological advantages, improves its competitiveness in the drug discovery market, and drives changes in the industry’s competitive landscape.
4 Global Purified Membrane Protein Market Size by Type
GPCRs are one of the largest and most diverse families of membrane receptors in eukaryotes. They play a crucial role in various therapeutic areas, including pain disorders, depression, insomnia, cancer, Alzheimer’s disease, and Parkinson’s disease. In 2024, the GPCR segment is expected to generate a revenue of 299.97 million USD, accounting for approximately 64.42% of the total market value. This segment is expected to maintain a robust growth rate due to its significance in drug discovery and development, with a projected CAGR of 15.03% from 2024 to 2028.
Ion channels are pore-forming proteins present in the membranes of all living cells. They ensure the flow of charged ions from one side of a membrane to the other, playing a vital role in fundamental physiological processes. In 2024, the ion channels segment is projected to generate a revenue of 70.18 million USD, representing 15.07% of the total market value. This segment is expected to grow at a CAGR of 17.94% from 2024 to 2028, driven by increasing research in neurology and cardiology.
Transporters are membrane proteins involved in the movement of molecules across cell membranes. They play a crucial role in nutrient capture, antibiotic efflux, protein secretion, toxin production, and other vital functions. In 2024, the transporters segment is expected to generate a revenue of 40.14 million USD, accounting for 8.62% of the total market value. This segment is projected to grow at a CAGR of 19.01% from 2024 to 2028, driven by advancements in drug delivery technologies and increasing interest in their role in pharmacology.
Table Global Purified Membrane Protein Market Size by Type in 2024
Type | Market Size (M USD) 2024 |
|---|---|
GPCR | 299.97 |
Ion Channels | 70.18 |
Transporters | 40.14 |
Others | 55.35 |
5 Global Purified Membrane Protein Market Size by Application
Among different applications, antibodies take the lead in terms of market revenue. It is projected to have a market value of 169.89 million US dollars in 2024. Antibodies play a vital role in modern medicine, from therapeutic applications in treating various diseases such as cancer and autoimmune disorders to diagnostic uses. The continuous research and development in antibody – based drugs drive the high demand for purified membrane proteins in this application area.
Small molecule screening follows, with a projected market revenue of 84.04 million US dollars in 2024. Small molecule drugs are a significant part of the pharmaceutical market. The process of small molecule screening requires purified membrane proteins as targets to identify potential drug candidates. This application is essential for drug discovery and development, aiming to find small molecules that can interact with specific membrane proteins to modulate their functions.
Drug discovery, as an important application, is expected to have a market value of 48.48 million US dollars in 2024. Purified membrane proteins serve as key elements in the drug discovery process. They help researchers understand the biological functions of proteins and identify potential drug targets. By studying the interaction between drugs and membrane proteins, scientists can develop more effective and targeted drugs.
Antibody discovery, another crucial application, is forecasted to generate a market revenue of 63.54 million US dollars in 2024. Similar to antibody – based applications, antibody discovery relies on purified membrane proteins to identify novel antibodies with specific binding affinities and functions. This area is at the forefront of immunotherapy research, aiming to develop antibodies that can specifically target disease – related proteins on cell membranes.
Clinical stage drug validation, which is vital for ensuring the safety and efficacy of drugs in clinical trials, is projected to have a market value of 34.61 million US dollars in 2024. Purified membrane proteins are used to validate the activity and mechanism of action of drugs in the clinical stage, providing essential data for regulatory approval.
Table Global Purified Membrane Protein Market Size by Application in 2024
Application | Market Size (M USD) 2024 |
|---|---|
Antibodies | 169.89 |
Small molecule screening | 84.04 |
Drug discovery | 48.48 |
Antibody discovery | 63.54 |
Clinical stage drug validation | 34.61 |
Others | 65.07 |
6 Global Purified Membrane Protein Market Size by Region
North America has been a dominant region in the global purified membrane protein market due to the presence of major pharmaceutical companies, advanced research facilities, and a strong focus on biotechnological advancements. In 2024, the market size in North America is projected to reach 241.72 M USD. This region’s growth is driven by the increasing investment in drug discovery and the development of new therapeutics, particularly in areas such as cancer treatment, neurological disorders, and cardiovascular diseases. The robust R&D infrastructure and the availability of skilled professionals contribute to the region’s leading position in the market.
Europe follows North America as a significant contributor to the global market, with a projected market size of 126.3 M USD in 2024. The European market benefits from a strong life sciences sector, supported by government initiatives and funding for research. Additionally, the region hosts several leading biotechnology companies and academic institutions that are actively involved in the development of membrane protein-related technologies. The growth in Europe is also influenced by the increasing demand for personalized medicine and the need for high-quality proteins in clinical trials and diagnostics.
China is emerging as a key player in the global purified membrane protein market, with a projected market size of 31.65 M USD in 2024. The rapid growth in China can be attributed to the government’s focus on strengthening the domestic pharmaceutical industry, increased investment in biotechnology research, and the growing need for advanced healthcare solutions to address the country’s aging population and rising prevalence of chronic diseases. China’s expanding biotechnology sector and the establishment of new research facilities are expected to drive further market growth in the coming years.
Figure Global Purified Membrane Protein Market Size (M USD) by Region in 2024
7 Global Purified Membrane Protein Market Analysis by Major Players
Creative Biostructure
Company Profile:
Creative Biostructure, established in 2005, is a leading provider of custom biotechnology and pharmaceutical services. The company specializes in structural biology and membrane protein technologies, offering a wide range of services to both academia and the biotech/pharmaceutical industries. With a strong team of experienced professionals, Creative Biostructure is known for solving the structure of challenging proteins, including GPCRs, ion channels, transporters, enzymes, and viral targets.
Business Overview:
Creative Biostructure provides comprehensive solutions in the field of membrane protein production and purification. The company’s services include custom membrane protein production, structural biology consulting, and advanced biophysical analysis. Their proprietary technologies enable the production of high-quality, functional membrane proteins, which are crucial for drug discovery and development.
Product Offered:
Creative Biostructure offers a wide range of products and services, including custom membrane protein production, structural biology consulting, and advanced biophysical analysis. They specialize in producing high-quality, functional membrane proteins, such as GPCRs, ion channels, and transporters, which are essential for drug discovery and development.
2023 Revenue and Gross Margin:
In 2023, Creative Biostructure generated a revenue of 41.05 million USD with a gross margin of 74.72%. This strong financial performance reflects the company’s leadership in membrane protein production and its ability to deliver high-quality products and services to the global market.
GenScript
Company Profile:
GenScript, established in 2002, is a global leader in life science R&D and manufacturing services. The company is renowned for its advanced gene synthesis technology and offers a comprehensive range of services and products across multiple platforms, including life science services, biologics CDMO, industrial synthetic products, and integrated cell therapy.
Business Overview:
GenScript’s business is divided into four major platforms: life science service and product platform, biologics contract development and manufacturing organization (CDMO) platform, industrial synthetic products platform, and integrated global cell therapy platform. The company’s expertise in gene synthesis and protein production has positioned it as a key player in the global market.
Product Offered:
GenScript offers a wide range of products and services, including custom gene synthesis, protein production, and biologics manufacturing. Their advanced technologies enable the production of high-quality, functional proteins, including membrane proteins, which are essential for drug discovery and development.
2023 Revenue and Gross Margin:
In 2023, GenScript generated a revenue of 14.07 million USD with a gross margin of 67.27%. This strong financial performance highlights the company’s ability to deliver high-quality products and services, leveraging its advanced technologies and global presence.
CUSABIO
Company Profile:
CUSABIO, established in 2007, is a leading provider of high-quality antibodies, recombinant proteins, and ELISA kits. The company is dedicated to supporting research in various fields, including cancer, cell biology, immunology, neuroscience, and epigenetics. With a strong focus on product quality and innovation, CUSABIO has established itself as a trusted supplier in the global market.
Business Overview:
CUSABIO offers a comprehensive range of products and services, including custom protein production, antibody development, and ELISA kits. The company’s expertise in protein production and purification has enabled it to deliver high-quality products to researchers and pharmaceutical companies worldwide.
Product Offered:
CUSABIO provides a wide range of products, including custom membrane protein production, recombinant proteins, antibodies, and ELISA kits. Their advanced technologies and strict quality control processes ensure that their products meet the highest standards, making them essential tools for life science research and development.
2023 Revenue and Gross Margin:
In 2023, CUSABIO generated a revenue of 7.76 million USD with a gross margin of 72.93%. This strong financial performance reflects the company’s commitment to delivering high-quality products and services, supported by its advanced technologies and global presence.